Anthracyclines: Clinical Trials

4 trials of Anthracyclines, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 1 terminated, 1 withdrawn. 4 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 14Completed 2, Terminated 1, Withdrawn 1
Phase 21Withdrawn 1

Follow Anthracyclines: new trials by email Literature Review of Anthracyclines trials Research Report on Anthracyclines

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Pulsed Electromagnetic Fields (PEMFs) - A Highly Selective Breast CAncer Treatment pLatform (PASCAL)
Pulsed electromagnetic fields (PEMFs), Device: Pulsed electromagnetic fields (PEMFs); Drug: Anthracycline OR Taxane - Breast Cancer
Phase 1CompletedNational University Hospital, Singapore142022-12-302026-03-13
HDM201 Added to CT in R/R or Newly Diagnosed AML
HDM201, cytarabine, anthracycline - Leukemia, Myeloid, Acute
Phase 1 / Phase 2WithdrawnNovartis Pharmaceuticals2019-11-152020-01-09
Safety and Efficacy Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-173/KEYNOTE-173)
Pembrolizumab, Nab-paclitaxel, Anthracycline (doxorubicin) - Triple Negative Breast Neoplasms
Phase 1CompletedMerck Sharp & Dohme LLC602016-01-272020-09-10
A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety and Efficacy of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer
Olaparib, Carboplatin, Anthracycline - Breast Cancer
Phase 1TerminatedAstraZeneca152015-11-062019-02-20

Conditions studied

Breast Neoplasms (2)  ·  Leukemia, Myeloid, Acute (1)  ·  Neoplasm, Residual (1)  ·  Parkinson Disease 4, Autosomal Dominant Lewy Body (1)  ·  Triple Negative Breast Neoplasms (1)

Sponsors

AstraZeneca (1)  ·  Merck Sharp & Dohme LLC (1)  ·  National University Hospital, Singapore (1)  ·  Novartis Pharmaceuticals (1)

Countries

Singapore (1)  ·  Spain (1)  ·  United States (1)

Top investigators

Judith Balmana (1)  ·  Rachel Wong, Medical Degree (1)  ·  Tiffany Traina (1)

Results publications

PMID 32278621, PMID 32450725, PMID 40069763

NIH funding

2015 (1), 2018 (1)